Education
About Us
Working with TipRanks
Follow Us
Spero Therapeutics (SPRO)
:SPRO
Earnings Data
Report Date
Nov 17, 2025TBA (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.25Last Year’s EPS
-0.32Same Quarter Last Year
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with significant achievements, particularly the successful Phase III trial for Tebipenem HBr and the improved financial metrics. However, challenges remain in the SPR720 program. Overall, the positive developments notably outweigh the negative aspects.Company Guidance
Successful Phase III PIVOT-PO Trial for Tebipenem HBr
The Phase III PIVOT-PO trial evaluating Tebipenem HBr for complicated urinary tract infections met its primary endpoint and was stopped early for efficacy, demonstrating non-inferiority to intravenous imipenem-cilastatin.
Extended Cash Runway
With the trial stopping early for efficacy, Spero achieved meaningful cost savings, extending the cash runway into 2028 based on their current operating plan.
Increased Revenue
Total revenue for the second quarter of 2025 was $14.2 million compared to $10.2 million for the second quarter of 2024, primarily due to collaboration revenue from GSK.
Reduction in Net Loss
Spero reported a net loss of $1.7 million for the second quarter of 2025 compared to a net loss of $17.9 million for the second quarter of 2024.
Significant R&D Expense Reduction
R&D expenses for the second quarter of 2025 were $10.7 million compared to $23.7 million for the same period in 2024, primarily due to reduced clinical expense related to the PIVOT-PO study.
SPRO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SPRO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 12, 2025 | $2.36 | $1.94 | -17.80% |
May 13, 2025 | $0.69 | $0.65 | -5.80% |
Mar 27, 2025 | $0.86 | $0.77 | -10.47% |
Nov 14, 2024 | $1.25 | $1.18 | -5.60% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Spero Therapeutics (SPRO) report earnings?
Spero Therapeutics (SPRO) is schdueled to report earning on Nov 17, 2025, TBA (Confirmed).
What is Spero Therapeutics (SPRO) earnings time?
Spero Therapeutics (SPRO) earnings time is at Nov 17, 2025, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SPRO EPS forecast?
SPRO EPS forecast for the fiscal quarter 2025 (Q3) is -0.25.